Ohio State Navbar

News


Congratulations Dr. Byrd


July 24, 2015

The American Society of Hematology will present the 2015 William Dameshek Prize to John C. Byrd, MD, of The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) for his contributions to the development of transformative treatments for chronic lymphocytic leukemia (CLL), most notably rituximab and ibrutinib. The rest of the story



Study Discovers Negative Regulator of Natural Killer Cell Maturation


June 05, 2015

STUDY DISCOVERS NEGATIVE REGULATOR OF NATURAL KILLER CELL MATURATION A study led by researchers at the OSUCCC – James has identified a regulatory pathway in natural killer (NK) cells that inhibits their maturation and homing behavior. NK cells are one of the body’s first lines of defense against viruses and cancer. The findings, published in the journal Immunity, could lead to strategies for boosting natural killer cell activity against cancer and viral infections. Jianhua Yu, PhD, a member of the Leukemia Research Program at the OSUCCC – James, was principal investigator. Read more: The rest of the story



Byrd Wins National Award for Innovative Clinical Research


June 05, 2015

BYRD WINS NATIONAL AWARD FOR INNOVATIVE CLINICAL RESEARCH John C. Byrd, MD, co-leader of the Leukemia Research Program at the OSUCCC – James, received the 2015 Charles G. Moertel Lecture Award from the Alliance for Clinical Trials in Oncology at the Alliance Spring Group Meeting held May 13-16 in Chicago. The Alliance presents the award annually to an investigator whose research within the National Cancer Institute (NCI) National Clinical Trials Network (NCTN) results in a major impact on community cancer practice. Read more: The rest of the story



Bloomfield Honored as a ‘Giant of Cancer Care'


June 05, 2015

Clara D. Bloomfield, MD, a Distinguished University Professor who serves as cancer scholar and senior adviser to the OSUCCC – James, was honored as one of 12 winners in the 2015 Giants of Cancer Care awards program sponsored by OncLive, a Web resource for physicians and other health professionals who focus on treating cancer. Read more: The rest of the story



James S. Blachly, MD, One of six receipients of a Young Investigator Award


May 05, 2015

James S. Blachly, MD, assistant professor in the Division of Hematology at Ohio State and member of the Leukemia Research Program at the OSUCCC – James, is one of six recipients of a Young Investigator Award from the National Comprehensive Cancer Network (NCCN) Foundation®. His grant is for $150,000 over two years for a project titled “Genomic Stratification and Prognostication of Adult Acute Myeloid Leukemia by Combination Mutation Status.” Blachly’s co-mentors for the award are Clara D. Bloomfield, MD, a Distinguished University Professor who also serves as OSU cancer scholar and senior adviser to the OSUCCC – James, and John C. Byrd, MD, director of the Division of Hematology and co-leader of the Leukemia Research Program. The rest of the story



OSU Researchers Contribute to ASCO's Choice for 'Cancer Advance of the Year'


March 31, 2015

OSU Researchers Contribute to ASCO’s Choice for ‘Cancer Advance of the Year’ Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) scientists played a key role in some of the recent research that has helped transform treatment for chronic lymphocytic leukemia (CLL)—a transformation that the American Society of Clinical Oncology (ASCO) calls the “Cancer Advance of the Year.” ASCO’s Clinical Cancer Advances 2015 notes that four new therapies, including two targeted drugs and two immunotherapies, have been approved by the FDA in just a year’s time for CLL, the most common form of adult leukemia. Much of the research leading to approval of the drug ibrutinib, one of the two targeted agents, was performed by scientists at the OSUCCC – James. The rest of the story



Researchers Detail Reasons for Ibrutinib Therapy Discontinuation in CLL


March 31, 2015

About 10 percent of patients with chronic lymphocytic leukemia (CLL) discontinued therapy with the Bruton tyrosine kinase (BTK) inhibitor drug ibrutinib because of disease progression during clinical trials, according to a study at the OSUCCC – James that was published in JAMA Oncology. Kami Maddocks,MD, of the Division of Hematology at Ohio State, was first author on the study, and Jennifer Woyach, MD, also of the Division of Hematology and a member of the Leukemia Research Program at the OSUCCC – James, was senior author. The rest of the story



Long Noncoding RNAs: A Novel Prognostic Marker in Older Patients With AML


March 31, 2015

A study led by researchers at the OSUCCC – James describes a novel marker that might help doctors choose the least toxic, most effective treatment for many older patients with acute myeloid leukemia (AML). AML occurs mainly in older patients and has a three-year survival rate of 5 to 15 percent. The study is published online in the Proceedings of the National Academy of Sciences. Clara D. Bloomfield, MD, a Distinguished University Professor who also serves as OSU cancer scholar and senior adviser to the OSUCCC – James, was principal investigator. Ramiro Garzon, MD, associate professor of internal medicine at Ohio State and member of the Leukemia Research Program at the OSUCCC – James, was first author. The rest of the story



BMT Nurses Win National Award for Patient Care Excellence


March 31, 2015

Nurses with the Blood and Marrow Transplant (BMT) Program at the OSUCCC – James have received national recognition for exceptional patient care and professional nursing practice with a three-year, bronze level Beacon Award for Excellence™ from the American Association of Critical-Care Nurses (AACN). The OSUCCC – James is the first BMT unit in the country to earn Beacon Award for Excellence recognition. The team includes 75 nurses. The rest of the story



$1.59 Million Grant Awarded


March 31, 2015

A team led by PIs Michael A. Caligiuri, MD, and Jianhua Yu, PhD, will use a five-year, $1.59 million grant to study how a dietary component from edible plants enhances the immune system’s ability to prevent AML or its recurrence. Caligiuri is director of the OSUCCC and CEO of The James. Yu is an assistant professor in the Division of Hematology and a member of the MCC Program. This project is a collaboration with co-investigator A. Douglas Kinghorn, PhD, DSc, a professor in the College of Pharmacy at Ohio State and member of the MCC Program. The rest of the story



Next